Mixed mullerian tumor: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{MV}} | {{CMG}} {{AE}} {{MV}} | ||
{{SK}} Mixed Müllerian tumor; MMMT; Malignant mixed Müllerian tumor | {{SK}} Mixed Müllerian tumor; MMMT; Malignant mixed Müllerian tumor; Carcinosarcoma of the uterus; Sarcomatoid carcinoma of the uterus; Malignant mesodermal mixed tumor; Metaplastic carcinoma | ||
==Overview== | ==Overview== | ||
'''Mixed Mullerian tumor''' (MMMT) is a rare [[uterine sarcoma]] or carcinosarcoma. | |||
==Historical Perspective== | ==Historical Perspective== | ||
* | *Mixed Mullerian tumor was first described by Ferriera and colleagues in 1951.<ref name="pmid16051326">{{cite journal |vauthors=Wright JD, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK |title=Cervical sarcomas: an analysis of incidence and outcome |journal=Gynecol. Oncol. |volume=99 |issue=2 |pages=348–51 |year=2005 |pmid=16051326 |doi=10.1016/j.ygyno.2005.06.021 |url=}}</ref> | ||
==Classification== | ==Classification== | ||
* | *Mixed Mullerian tumors are normally composed of both carcinomatous (epithelial) and sarcomatous (mesodermal) components. | ||
:* | *Mixed Mullerian tumor may be classified according to pathology findings into 2 types: | ||
:* | '''Epitheloid subtype''' | ||
:* | :*Endometroid adenocarcinoma (most common) | ||
* | :*Clear cell carcinoma | ||
:*Mucinous carcinoma | |||
:*Papillary-serous carcinoma | |||
'''Sarcomatoid subtype''' | |||
:*Undifferentiated sarcoma | |||
:*Rhabdomyosarcoma | |||
*Mixed Mullerian tumor may also be classified according to antomical location into 7 types: | |||
:*Uterine corpus | |||
:*Cervix | |||
:*Ovaries | |||
:*Fallopian tubes | |||
:*Vagina | |||
:*Peritoneum | |||
:*Extragenital sites | |||
==Pathophysiology== | ==Pathophysiology== | ||
*The pathogenesis of | *The pathogenesis of mixed Mullerian tumor is characterized by | ||
* | *Mixed Mullerian tumor | ||
*On gross pathology, | *On gross pathology, a large cervical mass is a characteristic finding of mixed Mullerian tumor. | ||
*On microscopic histopathological analysis, | *On microscopic histopathological analysis, high-grade stromal sarcoma, poorly differentiated epithelial cells, and angiolymphatic invasion are characteristic findings of mixed Mullerian tumor. | ||
==Causes== | ==Causes== | ||
* | * Mixed Mullerian tumor may be caused by precursor lesions, such as | ||
* | * Mixed Mullerian tumor is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s]. | ||
* There are no established causes for | * There are no established causes for mixed Mullerian tumor. | ||
==Differentiating | ==Differentiating mixed Mullerian tumor from other Diseases== | ||
* | |||
:* | *Mixed Mullerian tumor must be differentiated from other diseases that cause abnormal vaginal bleeding, abdominal pain, and metrorrhagia, such as: | ||
:* | :*Uterine leiomyosarcoma | ||
:* | :*Adenocarcinoma of the uterus | ||
:*Endometrial cancer | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
* The prevalence of | * The prevalence of mixed Mullerian tumor is approximately [number or range] per 100,000 individuals worldwide. | ||
* In [year], the incidence of | * In [year], the incidence of mixed Mullerian tumor was estimated to be [number or range] cases per 100,000 individuals in [location]. | ||
===Age=== | ===Age=== | ||
* | *The median age at diagnosis of Mixed Mullerian tumor is 66 years | ||
*Mixed Mullerian tumor is more commonly observed among patients aged between 50 and 60 years old. | |||
* | *Mixed Mullerian tumor is more commonly observed among postmenopausal women | ||
* | |||
===Race=== | ===Race=== | ||
*There is no racial predilection for | *There is no racial predilection for mixed Mullerian tumor. | ||
==Risk Factors== | ==Risk Factors== | ||
*Common risk factors in the development of | *Common risk factors in the development of mixed Mullerian tumor are exposure to radiation, excessive estrogen exposure, obesity, and nulliparity.<ref name="pmid20642852">{{cite journal |vauthors=Kanthan R, Senger JL, Diudea D |title=Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins |journal=World J Surg Oncol |volume=8 |issue= |pages=60 |year=2010 |pmid=20642852 |pmc=2913917 |doi=10.1186/1477-7819-8-60 |url=}}</ref> | ||
== Natural History, Complications and Prognosis== | == Natural History, Complications and Prognosis== | ||
*Early clinical features include postmenopausal vaginal bleeding, abdominal pain, and metrorrhagia. | |||
*Early clinical features include | *If left untreated, the majority of patients with mixed Mullerian tumor may progress quickly to develop lymph node invasion, metastasis, and death. | ||
*If left untreated, | *Common complications of mixed Mullerian tumor include | ||
*Common complications of | |||
*Prognosis is generally poor, and the 5-year survival rate of patients with Mixed Mullerian tumor is approximately 33% to 39%. | *Prognosis is generally poor, and the 5-year survival rate of patients with Mixed Mullerian tumor is approximately 33% to 39%. | ||
*Findings associated with good prognosis includes p16 and Mcl-1 genetic expression. | |||
== Diagnosis == | == Diagnosis == | ||
===Diagnostic Criteria=== | ===Diagnostic Criteria=== | ||
*The diagnosis of | *The diagnosis of mixed Mullerian tumor is made with biopsy. | ||
*Biopsy findings of mixed Mullerian tumor, include: | |||
: | :*Tumor with carcinomatous and sarcoma-like elements | ||
:* | :*Angiolymphatic invasion | ||
:* | |||
=== Symptoms === | === Symptoms === | ||
* | *Mixed Mullerian tumor is usually asymptomatic. | ||
*Symptoms of | *Symptoms of mixed Mullerian tumor may include the following:<ref name="pmid20642852">{{cite journal |vauthors=Kanthan R, Senger JL, Diudea D |title=Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins |journal=World J Surg Oncol |volume=8 |issue= |pages=60 |year=2010 |pmid=20642852 |pmc=2913917 |doi=10.1186/1477-7819-8-60 |url=}}</ref> | ||
:*[ | *Early symptoms may include: | ||
:*[ | :* Abnormal [[vaginal bleeding]], abnormal menstrual periods | ||
:*[ | :* [[Metrorrhagia]] in premenopausal women | ||
:*[ | :* Postmenopausal [[vaginal bleeding]] <ref name="pmid22513918">{{cite journal| author=Kong A, Johnson N, Kitchener HC, Lawrie TA| title=Adjuvant radiotherapy for stage I endometrial cancer. | journal=Cochrane Database Syst Rev | year= 2012 | volume= 4 | issue= | pages= CD003916 | pmid=22513918 | doi=10.1002/14651858.CD003916.pub4 | pmc=PMC4164955 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22513918 }} </ref> | ||
:*[ | :* Postcoital bleeding | ||
:*[ | *Advanced symptoms may include: | ||
:* [[Polyuria]] and [[dysuria]], If a tumor places pressure on the bladder or urethra | |||
:* [[Pelvic pain]] and [[dyspareunia]] | |||
:* [[Fatigue]] and unexplained [[weight loss]] | |||
=== Physical Examination === | === Physical Examination === | ||
*Patients with | *Patients with mixed Mullerian tumor may have a normal appearance. | ||
* | *Pelvic examination may be remarkable for: | ||
:* | :*Vaginal bleeding | ||
:*Enlarged uterus (advanced stage) | |||
:* | |||
=== Laboratory Findings === | === Laboratory Findings === | ||
*There are no specific laboratory findings associated with | *There are no specific laboratory findings associated with mixed Mullerian tumor. | ||
===Imaging Findings=== | ===Imaging Findings=== | ||
* | *Enhanced CT scan and MRI is the imaging modalities of choice for mixed Mullerian tumor. | ||
*On MRI, findings of mixed Mullerian tumor, may include: | |||
:*T1: predominantly isointense to both myometrium (75%) and endometrium (70%) | |||
*On | :*T2:hyper-intense to myometrium (90%) either hypo-intense (55%) or isointense (41%) to endometrium. | ||
* | *On enhanced CT, findings of mixed Mullerian tumor, may include: | ||
:*Heterogeneously hypodense and ill defined mass | |||
:*Dilatation of uterine cavity | |||
=== Other Diagnostic Studies === | === Other Diagnostic Studies === | ||
* | *Mixed Mullerian tumor may also be diagnosed using laparoscopy. | ||
== Treatment == | == Treatment == | ||
=== Medical Therapy === | === Medical Therapy === | ||
*There is no treatment for | *There is no treatment for mixed Mullerian tumor; the mainstay of therapy is supportive care. | ||
*The medical management for mixed Mullerian tumor, include: | |||
*The | |||
=== Surgery === | === Surgery === | ||
*Surgery is the mainstay of therapy for | *Surgery is the mainstay of therapy for mixed Mullerian tumor. | ||
* | *Total hysterectomy in conjunction with surgical staging is the most common approach to the treatment of mixed Mullerian tumor. | ||
* | *Different surgical procedures for the treatment of mixed Mullerian tumor, include: | ||
:*Total hysterectomy | |||
:*Bilateral salpingo-oophorectomy | |||
:*Pelvic and para-aortic lymph node dissection | |||
:*Cytology of peritoneal washings | |||
:*Omentectomy | |||
:*Biopsies of peritoneal surfaces | |||
=== Prevention === | === Prevention === | ||
*There are no primary preventive measures available for | *There are no primary preventive measures available for mixed Mullerian tumor. | ||
*Once diagnosed and successfully treated, patients with mixed Mullerian tumor are followed-up every 6 or 12 months. | |||
*Follow-up testing include pelvic examination, ultrasound, and biomarker monitorization. | |||
*Once diagnosed and successfully treated, patients with | |||
==References== | ==References== |
Revision as of 19:19, 5 April 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Synonyms and keywords: Mixed Müllerian tumor; MMMT; Malignant mixed Müllerian tumor; Carcinosarcoma of the uterus; Sarcomatoid carcinoma of the uterus; Malignant mesodermal mixed tumor; Metaplastic carcinoma
Overview
Mixed Mullerian tumor (MMMT) is a rare uterine sarcoma or carcinosarcoma.
Historical Perspective
- Mixed Mullerian tumor was first described by Ferriera and colleagues in 1951.[1]
Classification
- Mixed Mullerian tumors are normally composed of both carcinomatous (epithelial) and sarcomatous (mesodermal) components.
- Mixed Mullerian tumor may be classified according to pathology findings into 2 types:
Epitheloid subtype
- Endometroid adenocarcinoma (most common)
- Clear cell carcinoma
- Mucinous carcinoma
- Papillary-serous carcinoma
Sarcomatoid subtype
- Undifferentiated sarcoma
- Rhabdomyosarcoma
- Mixed Mullerian tumor may also be classified according to antomical location into 7 types:
- Uterine corpus
- Cervix
- Ovaries
- Fallopian tubes
- Vagina
- Peritoneum
- Extragenital sites
Pathophysiology
- The pathogenesis of mixed Mullerian tumor is characterized by
- Mixed Mullerian tumor
- On gross pathology, a large cervical mass is a characteristic finding of mixed Mullerian tumor.
- On microscopic histopathological analysis, high-grade stromal sarcoma, poorly differentiated epithelial cells, and angiolymphatic invasion are characteristic findings of mixed Mullerian tumor.
Causes
- Mixed Mullerian tumor may be caused by precursor lesions, such as
- Mixed Mullerian tumor is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
- There are no established causes for mixed Mullerian tumor.
Differentiating mixed Mullerian tumor from other Diseases
- Mixed Mullerian tumor must be differentiated from other diseases that cause abnormal vaginal bleeding, abdominal pain, and metrorrhagia, such as:
- Uterine leiomyosarcoma
- Adenocarcinoma of the uterus
- Endometrial cancer
Epidemiology and Demographics
- The prevalence of mixed Mullerian tumor is approximately [number or range] per 100,000 individuals worldwide.
- In [year], the incidence of mixed Mullerian tumor was estimated to be [number or range] cases per 100,000 individuals in [location].
Age
- The median age at diagnosis of Mixed Mullerian tumor is 66 years
- Mixed Mullerian tumor is more commonly observed among patients aged between 50 and 60 years old.
- Mixed Mullerian tumor is more commonly observed among postmenopausal women
Race
- There is no racial predilection for mixed Mullerian tumor.
Risk Factors
- Common risk factors in the development of mixed Mullerian tumor are exposure to radiation, excessive estrogen exposure, obesity, and nulliparity.[2]
Natural History, Complications and Prognosis
- Early clinical features include postmenopausal vaginal bleeding, abdominal pain, and metrorrhagia.
- If left untreated, the majority of patients with mixed Mullerian tumor may progress quickly to develop lymph node invasion, metastasis, and death.
- Common complications of mixed Mullerian tumor include
- Prognosis is generally poor, and the 5-year survival rate of patients with Mixed Mullerian tumor is approximately 33% to 39%.
- Findings associated with good prognosis includes p16 and Mcl-1 genetic expression.
Diagnosis
Diagnostic Criteria
- The diagnosis of mixed Mullerian tumor is made with biopsy.
- Biopsy findings of mixed Mullerian tumor, include:
- Tumor with carcinomatous and sarcoma-like elements
- Angiolymphatic invasion
Symptoms
- Mixed Mullerian tumor is usually asymptomatic.
- Symptoms of mixed Mullerian tumor may include the following:[2]
- Early symptoms may include:
- Abnormal vaginal bleeding, abnormal menstrual periods
- Metrorrhagia in premenopausal women
- Postmenopausal vaginal bleeding [3]
- Postcoital bleeding
- Advanced symptoms may include:
- Polyuria and dysuria, If a tumor places pressure on the bladder or urethra
- Pelvic pain and dyspareunia
- Fatigue and unexplained weight loss
Physical Examination
- Patients with mixed Mullerian tumor may have a normal appearance.
- Pelvic examination may be remarkable for:
- Vaginal bleeding
- Enlarged uterus (advanced stage)
Laboratory Findings
- There are no specific laboratory findings associated with mixed Mullerian tumor.
Imaging Findings
- Enhanced CT scan and MRI is the imaging modalities of choice for mixed Mullerian tumor.
- On MRI, findings of mixed Mullerian tumor, may include:
- T1: predominantly isointense to both myometrium (75%) and endometrium (70%)
- T2:hyper-intense to myometrium (90%) either hypo-intense (55%) or isointense (41%) to endometrium.
- On enhanced CT, findings of mixed Mullerian tumor, may include:
- Heterogeneously hypodense and ill defined mass
- Dilatation of uterine cavity
Other Diagnostic Studies
- Mixed Mullerian tumor may also be diagnosed using laparoscopy.
Treatment
Medical Therapy
- There is no treatment for mixed Mullerian tumor; the mainstay of therapy is supportive care.
- The medical management for mixed Mullerian tumor, include:
Surgery
- Surgery is the mainstay of therapy for mixed Mullerian tumor.
- Total hysterectomy in conjunction with surgical staging is the most common approach to the treatment of mixed Mullerian tumor.
- Different surgical procedures for the treatment of mixed Mullerian tumor, include:
- Total hysterectomy
- Bilateral salpingo-oophorectomy
- Pelvic and para-aortic lymph node dissection
- Cytology of peritoneal washings
- Omentectomy
- Biopsies of peritoneal surfaces
Prevention
- There are no primary preventive measures available for mixed Mullerian tumor.
- Once diagnosed and successfully treated, patients with mixed Mullerian tumor are followed-up every 6 or 12 months.
- Follow-up testing include pelvic examination, ultrasound, and biomarker monitorization.
References
- ↑ Wright JD, Rosenblum K, Huettner PC, Mutch DG, Rader JS, Powell MA, Gibb RK (2005). "Cervical sarcomas: an analysis of incidence and outcome". Gynecol. Oncol. 99 (2): 348–51. doi:10.1016/j.ygyno.2005.06.021. PMID 16051326.
- ↑ 2.0 2.1 Kanthan R, Senger JL, Diudea D (2010). "Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins". World J Surg Oncol. 8: 60. doi:10.1186/1477-7819-8-60. PMC 2913917. PMID 20642852.
- ↑ Kong A, Johnson N, Kitchener HC, Lawrie TA (2012). "Adjuvant radiotherapy for stage I endometrial cancer". Cochrane Database Syst Rev. 4: CD003916. doi:10.1002/14651858.CD003916.pub4. PMC 4164955. PMID 22513918.